Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 901–1,000 of 1,000
Henrique, T., da Silveira, N. J. F., Cunha-Volpato, A. H., Mioto, M. M., Stefanini, A. C. B., Fares, A. B., Andrade, J. G. D. S. C., Masson, C., López, R. V. M., Nunes, F. D., et al. (2016) · Database · doi:10.1093/database/baw026 · Cited by 10
Mináriková, P., Benešová, L., Hálková, T., Belšánová, B., Tučková, I., Bělina, F., Dušek, L., Zavoral, M., & Minárik, M. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/9408190 · Cited by 11
“This was mainly due to gastric biopsies processed into FFPE sections whose yields were at 70%, primarily due to low quality and, eventually, low amounts of DNA.”
Manmuan, S., Sakunrangsit, N., & Ketchart, W. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12806 · Cited by 10
Ota, S., Zhou, Z.-Q., & Hurlin, P. J. (2017) · Oncotarget · doi:10.18632/oncotarget.22816 · Cited by 10
“Overexpression of MYC and cyclin D1 can cause bypass of cell cycle checkpoints and promote tumor cell proliferation [14, 15].”
BackgroundMLF1IP promotes cells proliferation and apoptosis by regulating CyclinD1 in breast cancer.
Yang, F., Wang, Y.-H., Dong, S., Chen, C., & Huang, D.-P. (2017) · PubMed Central · Cited by 10
Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins
Goh, K. Y., & Lim, W. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-639 · Cited by 10
“Cyclin D1 is frequently upregulated in many cancer types (8).”
BackgroundBélanger, F., Roussel, C., Sawchyn, C., St-Hilaire, E., Gezzar-Dandashi, S., Kimenyi Ishimwe, A. B., Mallette, F. A., Wurtele, H., & Drobetsky, E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104900 · Cited by 9
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
BackgroundBatbold, U., & Liu, J. (2022) · Foods · doi:10.3390/foods11101517 · Cited by 9
“Previously, cyclin D1 activation has been reported to cause a shortened G1 phase, while its downregulation inhibits G1/S transition i many maligna cies [38].”
BackgroundMicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
Yamana, Y., Fujihara, S., Kobara, H., Oura, K., Samukawa, E., Chiyo, T., Okamura, M., Yamana, H., Tadokoro, T., Fujita, K., et al. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_104_20 · Cited by 9
Cyclin D1 promotes radioresistance through regulation of RAD51 in melanoma
Im, H., Lee, J., Lee, H. J., Kim, D. Y., Kim, E. J., & Yi, J. Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14877 · Cited by 9
Zhu, C., Zhou, H., Bao, M., Tang, S., Gu, X., Han, M., Li, P., & Jiang, Q. (2024) · Aquatic Toxicology · doi:10.1016/j.aquatox.2024.107046 · Cited by 9
Wang, X.-D., Lin, J.-H., & Hu, M.-H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108164 · Cited by 12
“Cyclins and cyclin-dependent kinases are main regulatory proteins in cell cycle, where cyclin D1 and cyclin B are crucial for G0/G1 and G2/M phases, respectively (41, 42).”
Aly, G. A., Sabra, S. A., Haroun, M., Helmy, M. W., & Moussa, N. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03829-1 · Cited by 10
“Mounting data support the dysregulation of mammalian cyclins as well as cyclin dependent kinases (CDKs) in cancer as well as their oncogenic capacity in experimental animal models (Musgrove et al. 2011).”
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Chen, W., Zhuang, X., Chen, Y., Yang, H., Shen, L., Feng, S., Min, W., Yuan, K., & Yang, P. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60846-6 · Cited by 17
Shen, Y., Wang, X., Jin, Y., Lu, J., Qiu, G.-M., & Wen, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2396 · Cited by 9
“…in cell proliferation, which is controlled by proteins that maintain the synchrony of cell growth, DNA synthesis, mitosis and cell division (21,22); base excision repair, which is related to DNA repair mechanisms; and lysine degradation, which is involved in a wide range of metabolic…”
Personalized medicine for metastatic breast cancer
Chen, T. W., & Bedard, P. L. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000015 · Cited by 9
“Cyclin-dependent kinases (CDKs) are a family of serine/threonine kinases that regulate cell cycle progression through interaction with specific cyclin proteins [56].”
BackgroundRizzolo, P., Navazio, A. S., Silvestri, V., Valentini, V., Zelli, V., Zanna, I., Masala, G., Bianchi, S., Scarnò, M., Tommasi, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12272 · Cited by 9
“In FBC, CCND1 is amplified in 5–20% of primary BCs, typically ER-positive BC, and is a prognostic biomarker with a potential therapeutic role [12, 13, 15, 37, 38].”
BackgroundThe D-Type Cyclins: A Historical Perspective
Sherr, C. J., & Siciński, P. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_1 · Cited by 16
Jing, W., Bi, Y., Wang, G., Zeng, S., Han, L., Yang, H., Wang, N., & Zhao, Y. (2020) · Lipids · doi:10.1002/lipd.12281 · Cited by 8
Essential role of protein kinase C βI in icariin-mediated protection against atherosclerosis
Zhang, Y., Xu, D., Huang, P., Zhang, Y., Li, Q., Fan, Z., & Ren, L. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab040 · Cited by 10
Jansen, J., Vieten, P., Pagliari, F., Hanley, R., Marafioti, M. G., Tirinato, L., & Seco, J. C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.597635 · Cited by 9
“CyclinD encoded by CCND1 is active throughout the whole cell cycle and regulates the activity of the cyclin-dependent Kinases, CDK4 and CDK6, which are necessary for the initiation of the G1 phase and the G1/S phase transition (Musgrove et al., 2011).”
BackgroundShining Light on Protein Kinase Biomarkers with Fluorescent Peptide Biosensors
Morris, M. C. (2022) · Life · doi:10.3390/life12040516 · Cited by 10
Kumar, B., Prasad, P., Singh, R., Sahu, R. K., Singh, A., Magani, S. K. J., & Hedau, S. T. (2023) · Molecular Omics · doi:10.1039/d2mo00285j · Cited by 10
Sebastian, P., Babu, J. M., Prathibha, R., Hariharan, R., & Pillai, M. R. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12175 · Cited by 9
Shamieh, S. E., Saleh, F., Assaad, S., & Farhat, F. S. (2019) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0027 · Cited by 9
Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
Fazeli, S., Paal, E. E., Maxwell, J. H., Burman, K. D., Nylén, E., & Khosla, S. (2019) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709619890942 · Cited by 9
“CDK4 protein plays a key role in the cell cycle progression across the G1/S phase transition.(15) A preclinical study of CDK4/6 inhibitor, ribociclib in PTC, and ATC cell lines has been shown to inhibit tumor growth with decreased expressions of pRB, pAKT, and Ki-67, and significantly increased tumor cell apoptosis.”
BackgroundBoichard, A., Richard, S. B., & Kurzrock, R. (2020) · Cancers · doi:10.3390/cancers12010166 · Cited by 9
“Similarly, many expect personalized medicine and combination therapy to be the future of cancer care [17–19] versus scripted monotherapies in many cases [20,21].”
BackgroundWei, J., Shi, Y., Zou, C., Zhang, H., Peng, H. C., Wang, S., Xia, L., Yang, Y. H., Zhang, X., Liu, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62106 · Cited by 9
“The DNA-binding domain of E2F4, a highly conserved region in the E2F family, can bind to the core sequence motif 5'-TTTSSCGC-3' in promoter regions [23,24].”
BackgroundLu, S., Mandava, G., Yan, G., & Lu, X. (2016) · Algorithms for Molecular Biology · doi:10.1186/s13015-016-0073-9 · Cited by 9
“CCND1 can be used as a therapeutic target in cancer therapy [26, 27].”
BackgroundNetworks and games for precision medicine
Biane, C., Delaplace, F., & Klaudel, H. (2016) · Biosystems · doi:10.1016/j.biosystems.2016.08.006 · Cited by 9
“In this signalling network model, the di(cid:27)erent pathways collaborate to regulate the activation of two targets: Cyclin D1 and Bax which are respectively the regulator of the G1/S transition during mitosis [30] and a pro-apoptotic factor initiating apoptosis [15].”
Shabestari, R. M., Alikarami, F., Bashash, D., Paridar, M., & Safa, M. (2018) · Europe PMC (PubMed Central) · doi:10.22088/ijmcm.bums.7.1.24 · Cited by 9
“Overexpression of cyclin D3 has been implicated in the pathogenesis of various types of cancers (33, 34).”
Park, Y., Cha, Y. E., Jang, M., Park, R., Namkoong, S., Kwak, J., Jang, I., & Park, J. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2002.02024 · Cited by 9
“In fact, cyclin D-cdk4 or cdk6 activation promotes cell cycle progression via the phosphorylation of the RB protein [14].”
BackgroundIdentification of cell cycle-targeting microRNAs through genome-wide screens
Hydbring, P., Wang, Y., Bogorad, R. L., Yin, H., Anderson, D. G., Cheng, L., & Siciński, P. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1380132 · Cited by 9
“Cyclins and CDKs are frequently overexpressed in human cancers.(1,3-7) Analyses of several murine cancer models revealed the requirement for specific cyclins and CDKs both in tumor initiation as well as in tumor maintenance.”
BackgroundShi, T., Fan, Q., Liu, S., & Zhang, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116309 · Cited by 9
KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenoma
Xu, Q., La, T., Ye, K., Wang, L., Wang, S., Hu, Y., Teng, L., Yan, L., Li, J., Zhang, Z., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1734 · Cited by 8
“70,71 The latter is known to be overexpressed in approximately 20% − 40% of PAs and is considered a driver of PA development and progression.”
BackgroundZheng, R., Prasad, A., Satyabola, D., Xu, Y., Roy, S., Yan, Y., Šulc, P., & Yan, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04918 · Cited by 9
PTEN defects in cancer, from gene to protein molecular causes and therapeutic targets
Khasarah, G., Nabilsi, D. A., Madani, O., Khazem, F., & Alsayed, R. (2025) · Discover Oncology · doi:10.1007/s12672-025-03465-4 · Cited by 10
“…recipient cells, it suppresses the PI3K/AKT signaling cascade, leading to reduced cyclin D1 expression (cyclin D1 is the regulatory protein that controls the progression of cells through the G1 phase of the cell cycle) [68], increased p27 levels, and subsequent cell cycle arrest [66].”
Stability of non-canonical nucleic acid structure as a potential modulator of cell fate
Takahashi, S., Tateishi‐Karimata, H., & Sugimoto, N. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1486 · Cited by 7
“Although cyclin D plays a central role in regulating the cell cycle, it has also been reported to act as an oncogene in many cancer cells [ 246 ].”
Sun, J., Liang, S., Liu, X., Zhang, S., Li, M., Zhang, Q., & Chen, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2294175 · Cited by 8
“In fact, CDK4/6 inhibitors are being developed to inhibit the activity of other CDKs (Musgrove et al., 2011), particularly CDK1(Malumbres & Barbacid, 2009).”
Harnessing autophagy: A potential breakthrough in digestive disease treatment
Eşrefoğlu, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i24.3036 · Cited by 8
Hanf, D., Fasching, P. A., Gaß, P., Beckmann, M. W., Hack, C. C., Heindl, F., Häberle, L., John, N., Erber, R., Press, M. F., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07545-x · Cited by 8
“Molecular mechanisms would also explain the poorer outcome in CCND1 -amplified/cyclin D1-overexpressing tumors, leading to increased cyclin D1 expression and inappropriate cyclin D-CDK 4/6 activity, and suggesting that CCND1 amplification could serve as a predictive biomarker [49, 50].”
CUEDC2 down-regulation is associated with tumor growth and poor prognosis in lung adenocarcinoma
Sun, L., Bai, L., Lin, G., Wang, R., Liu, Y., Cai, J.-H., Guo, Y., Zhu, Z., & Xie, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3930 · Cited by 9
“Cyclin D1 is a well-established human oncogene [25], which is over-expressed in lung cancer, breast cancer, melanoma and pancreatic cancer [25–28].”
BackgroundRUNX3 defines disease behavior in pancreatic ductal adenocarcinoma
Whittle, M. C., & Hingorani, S. R. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1076588 · Cited by 8
“The potential for increased local proliferation with inhibition of RUNX3 can be counterbalanced with complimentary strategies specifically targeting cell cycle mediators such as cyclin-dependent kinases 4 and 6 (CDK4/ 6).(10) As a marker of metastatic potential, however, RUNX3 can also potentially provide a tool to as…”
BackgroundLes inhibiteurs du cycle cellulaire et cancer du sein hormonodépendant
Sablin, M., Ricci, F., Loirat, D., Jobard, A., Basse, C., Romano, E., Tourneau, C. L., & Dieras, V. C. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.12.005 · Cited by 9
The Molecular Pathogenesis of Head and Neck Cancer
Hedberg, M. L., & Grandis, J. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00033-0 · Cited by 8
Keratin 19 interacts with GSK3β to regulate its nuclear accumulation and degradation of cyclin D3
Sharma, P., Tiufekchiev, S., Lising, V., Chung, S. W., Suk, J. S., & Chung, B. M. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-05-0255 · Cited by 17
Zhu, M., Wang, H., Ding, Y., Yang, Y., Xu, Z., Li, S., & Zhang, N. (2022) · The FASEB Journal · doi:10.1096/fj.202101914rr · Cited by 8
Mishra, A. K., Singh, S., Dayanandan, S., Banerjee, S., Chakraborty, S., Gopal, A. B., Samal, S., Poirah, I., Chakraborty, D., & Bhattacharyya, A. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155917 · Cited by 9
Dephosphorylation of the EGFR protein by calcineurin at serine 1046/1047 enhances its stability
Masaki, T., Habara, M., Shibutani, S., Hanaki, S., Sato, Y., Tomiyasu, H., & Shimada, M. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.12.017 · Cited by 9
Modeling breast cancer proliferation, drug synergies, and alternating therapies
He, W., Demas, D. M., Shajahan‐Haq, A. N., & Baumann, W. T. (2023) · iScience · doi:10.1016/j.isci.2023.106714 · Cited by 10
“0026 Calibrated (107) E2dep E2media in –E2 condition 1 3 10 (6)nM Fixed (108) percentagedeadt0 Percentage of dead cell at t = 0 0.”
MethodZhao, K., Zhang, H., Lin, J., Xu, S., Liu, J., Qian, X., Yong-bing, G., Ren, G., Lu, X., Chen, B., et al. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.03.031 · Cited by 8
“Cyclin D1 ( CCND1 ), the core gene of the cell cycle, is a frequently deregulated and relevant biomarker in certain tumors (6,7).”
Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors
Munakata, T., Inada, M., Tokunaga, Y., Wakita, T., Kohara, M., & Nomoto, A. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.05.011 · Cited by 8
“Although cyclin D consists of D1, D2, and D3 sub-types, D2 and D3 are not normally produced in the liver, while cyclin D1 is induced in hepatic tumor cells (Musgrove et al., 2011; Teramoto et al., 1999).”
BackgroundRobinson, S. C., Donaldson, N. S., Dvorkin‐Gheva, A., Longo, J., He, L., & Daniel, J. M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.007 · Cited by 8
Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6
Qie, S., & Diehl, J. A. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1610257 · Cited by 8
“As the result of gene amplification, increased transcription, or decreased protein degradation, cyclin D1 is overexpressed in human cancers, including pancreatic cancer, non-small cell lung carcinoma, breast cancer, head and neck squamous cell carcinoma, melanoma, endometrial cancer, esophageal squamous cell carcinoma…”
BackgroundKRAS as Potential Target in Colorectal Cancer Therapy
Eng, S.-K., Loh, T. H. T., Goh, B. H., & Lee, W.-L. (2019) · Springer eBooks · doi:10.1007/978-981-13-7154-7_12 · Cited by 10
Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression
Yan, B., Li, Y., Min, S., Zhang, P., Xu, B., Wang, Z., Zhang, W., Chen, J., Luo, G., & Liu, C. (2020) · BioMed Research International · doi:10.1155/2020/2753414 · Cited by 8
Low NDRG2 expression predicts poor prognosis in solid tumors: A meta-analysis of cohort study
Gu, A., Xu, J., Ye, J., & Zhang, C. (2020) · Medicine · doi:10.1097/md.0000000000022678 · Cited by 9
TELANG, N. T., Nair, H. B. B., & Wong, G. Y. (2021) · International Journal of Functional Nutrition · doi:10.3892/ijfn.2021.18 · Cited by 8
“Cyclin D1 functions as a G1 specific cyclin for G1 to S phase transition during cell cycle progression, and represents a potential thera‐ peutic target (17).”
BackgroundTranscriptome Analysis in Vulvar Squamous Cell Cancer
Prieske, K., Alawi, M., Jaeger, A., Wankner, M., Eylmann, K., Reuter, S., Lebok, P., Burandt, E., Blessin, N. C., Schmalfeldt, B., et al. (2021) · Cancers · doi:10.3390/cancers13246372 · Cited by 8
“CCND1 is considered an oncogene and encodes for the cyclin D1 protein that regulates the transition through the restriction point in the G1 to S phase, thereby promoting proliferation and growth, as well as resistance to chemotherapy and radiotherapy, and a shorter OS [33,34].”
BackgroundDyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras
Kamioka, H., Yogosawa, S., Oikawa, T., Aizawa, D., Ueda, K., Saeki, C., Haruki, K., Shimoda, M., Ikegami, T., Nishikawa, Y., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100759 · Cited by 10
“38 More-over, a strong correlation between tumorigenesis and self-renewal through Ras-Cyclin D2 activation has been demonstrated.”
CDK6 is a regulator of stem cells “Egr” to wake up
Guzmán, M. L. (2015) · Blood · doi:10.1182/blood-2014-11-609230 · Cited by 8
Pellerano, M., Naud‐Martin, D., Peyressatre, M., Prével, C., Teulade‐Fichou, M., Morris, M. C., & Mahuteau‐Betzer, F. (2016) · ChemBioChem · doi:10.1002/cbic.201500641 · Cited by 8
Association of RNF43 with cell cycle proteins involved in p53 pathway.
Xie, H., Xing, C., Cao, G., Wei, B., Xu, X., Song, P., Chen, L., Chen, H., Yin, S., Zhou, L., et al. (2015) · PubMed · Cited by 9
Petrohilos, C., Patchett, A. L., Hogg, C. J., Belov, K., & Peel, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-39901-0 · Cited by 7
Effects of the Cyclin D1 Polymorphism on Lung Cancer Risk - a Meta-analysis
Li, Y., Zhang, S., Geng, J., & Yu, Y. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.2325 · Cited by 7
Contact Normalization or Escape from the Matrix
Krishnan, H., & Goldberg, G. S. (2015) · Springer eBooks · doi:10.1007/978-94-017-7380-5_12 · Cited by 7
Role of MicroRNA-93 I in Pathogenesis of Left Ventricular Remodeling via Targeting Cyclin-D1
Zhang, J., Qin, L., Han, L., Zhao, Y., Jing, H., Song, W., & Shi, H. (2017) · Medical Science Monitor · doi:10.12659/msm.897542 · Cited by 7
“CCND1 overexpression in the mammary gland promotes mammary adenocarcinoma and hyperplasia and amplification of the same gene in stratified squamous epithelium in the esophagus and tongue promotes dysplasia and proliferation [22].”
BackgroundGENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems
Lee, B. K. B., Gan, C. P., Chang, J. K., Tan, J. L., Fadlullah, M. Z. H., Rahman, Z. A. A., Prime, S. S., Gutkind, J. S., Liew, C. S., Khang, T. F., et al. (2018) · Journal of Dental Research · doi:10.1177/0022034518759038 · Cited by 7
“Overexpression of CCND1 results in the activation of different pathways controlling cell cycle progression, migration, and differentiation (Musgrove et al. 2011).”
BackgroundCDK4/6 Dependence of Cyclin D1–Driven Parathyroid Neoplasia in Transgenic Mice
Costa‐Guda, J., Corrado, K. R., Bellizzi, J., Romano, R., Saria, E. A., Saucier, K., Rose, M. M., Shah, S., Alander, C. B., Mallya, S. M., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa159 · Cited by 8
Cardona‐Benavides, I. J., Misiewicz-Krzemińska, I., Rojas, E. A., Ramón, C. D., Sanz-Solas, A., Isidro, I. M., Quwaider, D., López-Guerrero, A. M., Cuadrado, M., Calasanz, M. J., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283445 · Cited by 7
Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma
Lu, K., Zhang, M., Qin, H., Shen, S., Song, H., Jiang, H., Zhang, C., Xiao, G., Tong, L., Jiang, Q. Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.013 · Cited by 7
“Cyclin D1 has been found to be upregulated in many different types of cancers, including breast cancer, mantle cell lymphoma (MCL), urinary bladder cancer, prostate cancer, non-small cell lung cancer, and colon cancer, etc. 6-13 .”
In vitro and in vivo effects of curcumin on oral cancer: a systematic review
Ridho, F. M., Syachputra, A. J., Fahrudin, P., Nurhuda, A., Nurliana, N., & Latuamury, N. S. (2024) · Current Biomedicine · doi:10.29244/currbiomed.2.2.101-115 · Cited by 11
“These components are crucial for controlling the cell cycle in cancer (Musgrove et al. , 2011; Choi et al. , 2012).”
BackgroundKang, H., Yun, S., Shin, S., Youn, D. H., Son, G., Lee, J. J., & Hong, J. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810119 · Cited by 7
“One of the mechanisms regulating cyclin D overexpression is a reduction in the levels of the miRNAs targeting CCND1 [40].”
BackgroundHuang, C., Hsieh, N., Pan, M., Li, C., Chou, Y., Chiou, Y., & Lee, M. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.11.006 · Cited by 7
Ambrosio, E. P., Silveira, C. G. T., Drigo, S. A., Sacomano, V. D. S., Molck, M. C., Rocha, R. M., Domingues, M. A. C., Soares, F. A., Kowalski, L. P., & Rogatto, S. R. (2013) · Tumor Biology · doi:10.1007/s13277-013-0866-0 · Cited by 7
“, INK4 family members), and differences in the spreading pattern affected by the anatomical features and lymphatic drainage, among others, could contribute to these findings [49].”
BackgroundYan, Y.-Y., Fu, L., Zhang, W., Ma, H.-S., Ma, C. G., Liang, Y.-J., Liu, B. Y., Yu, J. Z., Wu, Q. Z., & Dong, Y. M. (2014) · PubMed · Cited by 7
Effects of LG268 on Cell Proliferation and Apoptosis of NB4 Cells
Xu, T., Zhong, L., Gan, L., Xiao, C., Shan, Z., Yang, R., Song, H., Li, L., & Liu, B. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.15507 · Cited by 7
“Cyclin D1 is closely associated with the proliferation of cancer cells, and it has an important role in the G1/S-phase transition, which may promote the occurrence of tumors [29-30].”
BackgroundJiang, F., Wang, Y., Du, S., Jin, H., & Han, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-1325-5 · Cited by 7
“Overexpression of cyclin D1 results in activated CDK, rapid cell growth under conditions of restricted mitogenic signaling, bypass of key cellular checkpoints and ultimately cell proliferation [7, 11].”
BackgroundCircRNAs: a family number of miRNA regulatory transcriptome in laryngeal carcinoma
Miao, L., Feng, G., & Yuan, H. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24038 · Cited by 7
Yajima, I., Tazaki, A., Ohgami, N., & Kato, M. (2022) · PubMed Central · Cited by 9
Zhao, J., Wu, Y., Xiao, T., Cheng, C., Zhang, T., Gao, Z., Hu, S., Ren, Z., Yu, X., Yang, F., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06866-7 · Cited by 7
Wang, K. S., Ma, J., Mi, C., Li, J., Lee, J. J., & Jin, X. (2016) · Oncology Reports · doi:10.3892/or.2016.4576 · Cited by 7
Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas
Zlámalíková, L., Moulis, M., Šálek, D., Jarkovský, J., Šmarda, J., & Šmardová, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4658 · Cited by 8
“Cyclins D1, D2 and D3 share both structural and functional similarities but they are expressed in a tissue-specific manner (1,2).”
BackgroundChaves‐Ferreira, M., Krenn, G., Vasseur, F., Barinov, A., Gonçalves, P., Azogui, O., Cumano, A., Li, Z., Pellegrini, S., Rocha, B., et al. (2016) · Biology Direct · doi:10.1186/s13062-016-0122-9 · Cited by 7
“well known to control gene expression [4–7].”
Leigh, A. B., Cheung, H. P., Lin, L., Ng, T. B., Lao, L., Zhang, Y., Zhang, Z., Tong, Y., & Sze, S. C. W. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416651969 · Cited by 7
“Several preclinical studies supported that panCDK inhibitors work synergistically with cytotoxic agents, such as 5-fluorouracil and cisplatin against cancer cells.(44) Since TXL formula and its BU fraction can downregulate cyclin D1, it is worthwhile to further study if TXL and/or its fraction may help develop an alte…”
BackgroundWang, J., Wang, N., Li, Z.-J., Yang, L., Jing, Y.-G., Cheng, J., & Li, J. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.08.003 · Cited by 7
Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines
Roell, K. R., Havener, T. M., Reif, D. M., Jack, J., McLeod, H. L., Wiltshire, T., & Motsinger‐Reif, A. A. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00829 · Cited by 7
Wang, J., Li, A., Zhang, L., Veeraraghavan, V., & Mohan, S. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_2_20 · Cited by 7
Min, Z., Wan, L., He, X., Qi, X., Liu, F., & Zhang, D. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0479-8 · Cited by 7
“CCND1, a key regulatory protein, plays an important role in the transition from the G1 to S phase of the cell cycle [15], and its deregulation has been implicated in the pathogenesis of several types of cancers [26,27].”
BackgroundUnexpected Outcomes of CDK4/6 Inhibition
Choi, Y. J., & Siciński, P. (2013) · Oncotarget · doi:10.18632/oncotarget.912 · Cited by 7
Djakbarova, U., Madraki, Y., Chan, E. T., Wu, T., Atreaga-Muniz, V., Akatay, A. A., & Kural, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.07.579324 · Cited by 9
“While further investigation is necessary to determine the reciprocal relationship between checkpoint activation and tension induced adhesion mode switch, our data further underscore the rationale of targeting Cdk4/6 activity as a therapeutic strategy in oncology (176,177).”
Okano, Y., Yamauchi, T., Fukuzaki, R., Tsuruta, A., Yoshida, Y., Tsurudome, Y., Ushijima, K., Matsunaga, N., Koyanagi, S., & Ohdo, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107890 · Cited by 10
“Notably, D-type cyclins are recognized for their involvement in human oncogenesis (38).”
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
Mo, Z., Groocock, L., Wood, S., Jankeel, D., Mendy, D., Watson, E. R., Yan, K., Deb, G., Côte, M., Janardhanan, P., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0059 · Cited by 7
Tang, Y., Li, Y., Zhang, C.-R., Ye, Y., Qiu, T., Zhu, Z., & Zhao, J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468357 · Cited by 6
“Cyclin D activates CDK4/6, facilitating the transition from the G1 phase to the S phase [7], which results in the phosphorylation of retinoblastoma protein (Rb) and the release of Rb-bound E2F [8,9].”
Boonyarat, C., Sakurai, H., Hayakawa, Y., Chaiwiwatrakul, S., Kaewamatawong, R., Supapaan, T. S., Duangjit, S., Sethabouppha, B., & Waiwut, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115011 · Cited by 6
“A key molecular event in cervical carcinogenesis includes the dysregulation of the G1-to-S phase transition, characterized by alterations in cyclin D1, CDKs, and the retinoblastoma (RB) tumor suppressor pathway [16,17].”
p63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma
Pecorari, R., Mancini, M., Smirnov, A., Corleone, G., Novelli, F., Lena, A. M., Canonico, M. F., Montanaro, M., Cappello, A., Sacconi, A., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500579122 · Cited by 6
Blanca, A., Sánchez, Á., Valiente, J. C., Ruiz-García, J., Gómez, E. G., Antonio Lopez-beltran, B., & Tapia, M. J. R. (2017) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2017.02.014 · Cited by 6
Blanca, A., Sánchez, Á., Carrasco‐Valiente, J., Ruiz-García, J., Gómez‐Gómez, E., Antonio Lopez-beltran, B., & Tapia, M. J. R. (2016) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2016.09.003 · Cited by 6
Cruz, M. R. D. S., Reinert, T., & Cristofanilli, M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.965 · Cited by 7
“Furthermore, CDK4 and CDK6 have been implicated in tumor angiogenesis, and cyclin D1 has been related to ER transcription control, interaction with androgen and PPAR receptors.(20,21) Genomic and chromosomal instability may also be a consequence of abnormal CDK activation.”
BackgroundKurozumi, A., & Lupold, S. E. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.05.014 · Cited by 6
“CCND1 is an established human proto-oncogene and critical regulator of the G1/S cell cycle transition [31].”
Background
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.